

## **THC – the unsolicited Cannabinoid in supplements**

THC – the main psychoactive cannabinoid in the Cannabis plant - causes problems in several respects for every producer of CBD-related dietary supplements.

THC is naturally abundant in full spectrum extracts from industrial hemp. While the hemp raw material may contain up to 0.2% THC, there are no harmonized accepted threshold levels in the EU for THC in finished products – in most jurisdictions, however, they are far below that number. EFSA has set the stage by establishing an acute reference dose (ARfD) of 1 µg Δ9-THC/kg bw, which is currently challenged by the EIHA.

Sanity Group's presentation will show different approaches from individual EU countries and make suggestions for a way forward on the EU level.

Apart from the naturally occurring THC in CBD products, it is often stated that CBD is metabolized into THC under physiological conditions in the stomach. This would cause positive results from forensic drug testing after consumption of CBD products. Sanity Group's presentation will provide the status of current research and evaluate if the transformation of CBD into THC through metabolization could pose a risk for consumers.

## **Contact**

Dr. Iris Hardewig  
Sanity Group GmbH  
Jablonskistr. 27  
10405 Berlin  
Deutschland  
Telefon: +49 (0) 30 72621395  
E-Mail: [iris.hardewig@sanitygroup.com](mailto:iris.hardewig@sanitygroup.com)

Website: <https://sanitygroup.com/>

Facebook: <https://www.facebook.com/sanitygroup/>

LinkedIn: <https://www.linkedin.com/company/sanitygroup/about/>

Twitter: <https://twitter.com/SanityGroupEU>